NEW YORK (GenomeWeb News) — A total of up to $30 million will go to 12 or 14 investigators in 2010 to fund new and renewal studies in the Pharmacogenomics Research Network program, the National Institutes of Health said Friday.
The PGRN is a consortium of interdisciplinary groups that study how genetics affect drug responses in both positive and adverse ways. These projects aim to use genomic studies to identify and validate genes involved in biological pathways, to identify variation in genes and biological pathways, to understand the consequences of genetic variation on certain drugs being studied, and to learn more about the clinical implications of using genotyping to predict drug responses.
Scientists applying for the funding may request direct costs of around $1 million to $1.5 million per year for a total of up to five years.
Although past PGRN groups have focused on areas including cardiovascular diseases, cancers, asthma, depression and addiction, researchers applying for funding may propose studying other illnesses.
The PGRN includes participation from the National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Drug Abuse; National Institute on Mental Health; and National Institute of Child Health and Human Development.